nNIF peptide

nNIF peptide (0.1-1 mg/kg; i.v.; administered twice) dose-dependently improves survival in a sepsis model of Swiss Webster mice. The 6-day survival rates reach 70% and 73% in the 0.5 mg/kg and 1 mg/kg dose groups, respectively. Meanwhile, it reduces NET formation, alleviates disease severity, and decreases peritoneal TNF-α levels^[2].
nNIF peptide (1 mg/kg; i.v.; administered twice), as an adjuvant therapy to suboptimal Meropenem (HY-13678), increases the 6-day survival rate to 90% in a sepsis model of Swiss Webster mice, while improving disease severity and normalizing late-stage bacterial CFU levels^[2].
nNIF peptide (10 mg/kg; i.p.; two administrations) significantly increases the survival rate of neonatal mice with cecal slurry-induced infectious peritonitis to 47%, while reducing peritoneal neutrophil extracellular trap (NET) formation, proinflammatory cytokine levels and circulating platelet-neutrophil aggregates, and increasing peritoneal neutrophil counts and bacterial loads^[3].
nNIF peptide (10 mg/kg; i.p.; 2 administrations), as an adjuvant therapy, significantly increases the survival rate of neonatal mice with cecal homogenate-induced infectious peritonitis receiving sub-dose Meropenem to 83-100%^[3].
nNIF peptide (10 mg/kg; i.p.; 2 administrations) significantly increases the survival rate of neonatal mice with cecal slurry-induced infectious peritonitis to 18%^[3].